PEDaily (ID: pedaily2012) reported on May 25,On the 25th, Abiosciences (Analytical Biosciences) successfully completed its Series A4 financing round. This round of financing was`Sequoia Capital`China Fund led the investment, along with IDG Capital,Green Pine Capital、 Primavera Capital Group also participated in this round of financing.

This marks another round of financing for Abiosciences following the strategic investment from BioMap in February this year. Previously, Abiosciences has already obtainedSoftBank China Capital、Xingze Capital's investment, and IDG Capital's continued investment.The successive backing of numerous renowned investment institutions underscores the capital market's strong preference for single-cell mechanism research platforms and bioinformatics big data/AI platforms, as well as its high recognition of Abiosciences. This has also endowed Abiosciences with a more robust cash flow, laying a solid foundation for its rapid development.

This round of financing will enable Abiosciences to further systematically expand and accelerate the translational applications of its single-cell big data platform, single-cell one-stop data analysis platform, and related technologies in innovative drug R&D; strengthen the development of the company’s Drug Target R&D Center, Candidate Macromolecule Mechanism R&D Center, and High-Performance Bio-Computing/AI Platform, thereby enhancing its core competitiveness in the efficient processing and in-depth interpretation of massive single-cell data; advance the company’s initiatives in novel drug target discovery, immunobiological validation, antibody development, biomarker discovery, basic research, and clinical studies, facilitating the establishment of its comprehensive market advantages and international leadership; and simultaneously further expand the commercial footprint and progress of its systematic and efficient international operational framework.

Founder, Abiosciences, Peking University Beijing Advanced Innovation Center for Biomedical Sciences (BIOPIC)Zemin ZhangProf.Indicates:

Currently, the biomedical sector is rapidly advancing toward greater precision, quantification, and big data-driven methodologies, with single-cell genomics data emerging as the cornerstone of drug discovery, clinical diagnostics, and basic scientific research. Leveraging single-cell sequencing technologies, artificial intelligence, and proprietary bioinformatics analysis methods, Abiosciences is rapidly and efficiently mapping single-cell precision atlases of human diseases, providing a robust data foundation and in-depth analytical support for drug development targeting cancer and other conditions. This round of financing will significantly accelerate the development and maturation of Abiosciences’ single-cell big data platform, intelligent analysis workflows, and solutions, enabling their broader and deeper integration into the scientific research and R&D initiatives of Abiosciences and its partners, thereby accelerating global efforts to conquer major diseases such as cancer.

CEO of AbiosciencesWang YangDr. ZhouIndicates:

The transformative power of single-cell technology has become an industry consensus, poised to revolutionize biomedicine. Abiosciences is deeply honored to partner with numerous strategic capital investors to explore the highly promising single-cell market and witness a new era of biomedicine driven by single-cell data. We are delighted to receive the continued recognition and unwavering from our numerous investor partners,Yu Lisupport. With the rapid advancement of single-cell sequencing technology and the exponential accumulation of data, the difficulty of processing related data is intensifying daily. How to efficiently process, deeply mine, and interpret massive single-cell data has become a critical "bottleneck" in leveraging single-cell data for drug development and translational applications. Building upon Professor Zhang Zemin's extensive research foundation and the sustained development and unremitting efforts of the entire Abiosciences team over the past two years, Abiosciences has forged unique core competitiveness in this domain. The new injection of capital will significantly empower Abiosciences to further expand its leading edge in market competition and solidify its market leadership in single-cell multi-omics big data/AI platforms and new drug R&D.

Han Jiang, Managing Director, Sequoia Capital China Fund：

HongShan has long been focused on foundational breakthroughs in new technologies for drug discovery and diagnostic development, with the growing maturity of single-cell genomics being a prime example. We fully recognize the accomplishments achieved by Abiosciences’ founding team, the company’s strategic direction for future development, and its highly anticipated innovative breakthroughs. HongShan will continue to leverage its professional team with deep industry expertise to support leading innovators like Abiosciences. We will connect the company with globally accessible resources, empower its growth, and assist in advancing its technological progress and product development, ultimately benefiting society.

Pang Zixuan, Vice President of IDG Capital：

As the earliest and sole investor, IDG Capital has participated in the founding and development of Abiosciences over the past two years and has continued to increase its investment in subsequent funding rounds. Over the past two years, we have witnessed remarkable progress by the Abiosciences team under the leadership of Professor Zemin Zhang, and we remain firmly optimistic about the broad application prospects of single-cell big data. IDG Capital will continue to support the development of Abiosciences and the single-cell sector, and we look forward to the company’s technology platform continuously delivering significant translational breakthroughs across multiple fields.

Founder of Green Pine CapitalPartnerLuo Fei：

As an investor in Abiosciences' latest funding round, we are confident that under the leadership of Professor Zhang Zemin and the management team, the application of single-cell and bioinformatics platforms to the diagnosis and treatment of major diseases will enable the discovery of novel diagnostic and therapeutic targets, thereby facilitating the development of breakthrough innovative therapeutics.

Zou Ling, Co-Head of Primavera Capital：

Single-cell sequencing technology is accelerating its translation from research to clinical application. Particularly in tumor immunology, the unique advantages of single-cell sequencing in analyzing intratumoral heterogeneity and the immune microenvironment grant it broad application prospects. We are highly confident in Professor Zhang Zemin and the Abiosciences team’s ability to translate academic achievements into industry practice, and we anticipate that Abiosciences will emerge as a global leader in the single-cell sector in the future.